State Street’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-1,859,461
| Closed | -$70M | – | 4535 |
|
|
2021
Q1 | $70M | Buy |
1,859,461
+877,537
| +89% | +$21.9M | ﹤0.01% | 1494 |
|
|
2020
Q4 | $16.7M | Buy |
981,924
+265,100
| +37% | +$3.32M | ﹤0.01% | 2347 |
|
|
2020
Q3 | $3.37M | Buy |
716,824
+44,984
| +7% | +$228K | ﹤0.01% | 2980 |
|
|
2020
Q2 | $4.1M | Buy |
671,840
+56,815
| +9% | +$234K | ﹤0.01% | 2854 |
|
|
2020
Q1 | $1.4M | Sell |
615,025
-11,530
| -2% | -$48.9K | ﹤0.01% | 3213 |
|
|
2019
Q4 | $2.88M | Sell |
626,555
-36,804
| -6% | -$146K | ﹤0.01% | 3110 |
|
|
2019
Q3 | $2.57M | Sell |
663,359
-5,676
| -0.8% | -$31.1K | ﹤0.01% | 3124 |
|
|
2019
Q2 | $4.03M | Sell |
669,035
-642,078
| -49% | -$6.14M | ﹤0.01% | 2938 |
|
|
2019
Q1 | $17.6M | Buy |
1,311,113
+37,978
| +3% | +$433K | ﹤0.01% | 2128 |
|
|
2018
Q4 | $11.8M | Sell |
1,273,135
-248,586
| -16% | -$2.96M | ﹤0.01% | 2340 |
|
|
2018
Q3 | $21.2M | Sell |
1,521,721
-384,462
| -20% | -$5.72M | ﹤0.01% | 2135 |
|
|
2018
Q2 | $30.1M | Sell |
1,906,183
-118,402
| -6% | -$2.07M | ﹤0.01% | 1848 |
|
|
2018
Q1 | $34.8M | Buy |
2,024,585
+281,591
| +16% | +$5.49M | ﹤0.01% | 1675 |
|
|
2017
Q4 | $38.2M | Buy |
1,742,994
+734,217
| +73% | +$23.6M | ﹤0.01% | 1608 |
|
|
2017
Q3 | $41.3M | Sell |
1,008,777
-345,820
| -26% | -$10.9M | ﹤0.01% | 1499 |
|
|
2017
Q2 | $40.8M | Buy |
1,354,597
+105,077
| +8% | +$3.28M | ﹤0.01% | 1488 |
|
|
2017
Q1 | $45.2M | Buy |
1,249,520
+255,488
| +26% | +$11.3M | ﹤0.01% | 1384 |
|
|
2016
Q4 | $49.8M | Sell |
994,032
-67,029
| -6% | -$3.52M | ﹤0.01% | 1269 |
|
|
2016
Q3 | $55.7M | Buy |
1,061,061
+3,225
| +0.3% | +$154K | 0.01% | 1173 |
|
|
2016
Q2 | $43.7M | Buy |
1,057,836
+234,648
| +29% | +$10.2M | ﹤0.01% | 1255 |
|
|
2016
Q1 | $33.4M | Buy |
823,188
+173,838
| +27% | +$5.97M | ﹤0.01% | 1377 |
|
|
2015
Q4 | $26.9M | Sell |
649,350
-861,896
| -57% | -$28.9M | ﹤0.01% | 1505 |
|
|
2015
Q3 | $23.3M | Buy |
1,511,246
+70,658
| +5% | +$1.52M | ﹤0.01% | 1652 |
|
|
2015
Q2 | $35.8M | Buy |
1,440,588
+326,074
| +29% | +$7.26M | ﹤0.01% | 1464 |
|
|
2015
Q1 | $25.5M | Buy |
1,114,514
+906,383
| +435% | +$22.9M | ﹤0.01% | 1683 |
|
|
2014
Q4 | $5.62M | Buy |
208,131
+19,115
| +10% | +$329K | ﹤0.01% | 2507 |
|
|
2014
Q3 | $2.22M | Buy |
189,016
+16,650
| +10% | +$210K | ﹤0.01% | 2966 |
|
|
2014
Q2 | $2.68M | Buy |
172,366
+89,717
| +109% | +$1.29M | ﹤0.01% | 2924 |
|
|
2014
Q1 | $1.63M | Buy |
82,649
+40,737
| +97% | +$692K | ﹤0.01% | 3139 |
|
|
2013
Q4 | $704K | Buy |
+41,912
| New | +$521K | ﹤0.01% | 3308 |
|
State Street's FPRX Position: Q2 2021 in Review
State Street sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 1,859,461 shares — an estimated $70M sold.
State Street first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $70M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- State Street reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- State Street sold 1,859,461 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $70M.
- State Street first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- State Street's Five Prime Therapeutics, Inc. position peaked at $70M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on State Street's 13F filing for Q2 2021, filed 16 Aug 2021.